Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Balance Sheet

Financials in millions KRW. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	98,674	115,378	219,433	125,022	268,651	458,975
Short-Term Investments	36,135	58,334	3,058	176,390	25,584	-
Trading Asset Securities	-	-	-	-	9,035	377.68
Cash & Short-Term Investments	134,809	173,712	222,492	301,412	303,270	459,353
Cash Growth	-40.29%	-21.92%	-26.18%	-0.61%	-33.98%	849.10%
Accounts Receivable	421.77	607.07	391.6	132.72	-	-
Receivables	421.77	607.07	391.6	132.72	-	-
Inventory	31,448	26,995	18,103	7,146	2,157	-
Prepaid Expenses	-	1,641	2,733	2,731	-	-
Other Current Assets	4,976	7,049	6,632	53.44	6,139	584.08
Total Current Assets	171,655	210,004	250,352	311,476	311,566	459,937
Property, Plant & Equipment	343,603	341,657	327,062	310,438	38,342	6,437
Long-Term Investments	-	-	-	-	74,710	24,159
Goodwill	10,886	10,530	10,785	10,192	-	-
Other Intangible Assets	30,964	30,056	31,327	29,877	4,288	450.33
Long-Term Deferred Charges	157,114	152,882	91,643	78,843	61,024	108,573
Other Long-Term Assets	532.89	525.18	551.5	775.14	9,883	4,611
Total Assets	714,755	745,654	711,720	741,600	499,813	604,166
Accounts Payable	2,299	5,864	2,282	462.15	2,624	-
Accrued Expenses	-	4,872	5,975	6,150	4,923	3,552
Short-Term Debt	95,439	95,939	36,954	31,188	-	2,873
Current Portion of Long-Term Debt	-	14,083	10,891	31,176	-	-
Current Portion of Leases	975.45	1,018	950.81	1,682	1,593	1,326
Current Unearned Revenue	-	-	-	-	-	565
Other Current Liabilities	48,024	43,546	88,805	64,231	32,654	5,730
Total Current Liabilities	146,738	165,322	145,857	134,888	41,794	14,046
Long-Term Debt	29,988	32,498	40,247	50,190	-	-
Long-Term Leases	613.13	641.93	624.04	1,326	2,656	3,571
Long-Term Unearned Revenue	-	-	-	-	25,427	11,588
Long-Term Deferred Tax Liabilities	7,478	7,310	7,755	7,368	-	-
Other Long-Term Liabilities	30,624	31,572	1,734	1,593	0	-
Total Liabilities	215,441	237,343	196,219	195,365	69,877	29,206
Common Stock	737,175	713,096	730,340	690,175	679,713	594,072
Additional Paid-In Capital	-32,673	-31,606	7,865	7,286	7,175	-
Retained Earnings	-287,748	-266,271	-294,797	-246,151	-259,601	-27,954
Comprehensive Income & Other	-7,893	-4,209	-4,321	-798.76	2,649	8,843
Total Common Equity	408,860	411,010	439,087	450,511	429,936	574,961
Minority Interest	90,454	97,301	76,414	95,724	-	-
Shareholders' Equity	499,315	508,311	515,502	546,235	429,936	574,961
Total Liabilities & Equity	714,755	745,654	711,720	741,600	499,813	604,166
Total Debt	127,015	144,179	89,667	115,561	4,249	7,771
Net Cash (Debt)	7,794	29,533	132,825	185,851	299,020	451,582
Net Cash Growth	-93.23%	-77.77%	-28.53%	-37.85%	-33.78%	892.04%
Net Cash Per Share	129.78	490.33	2215.00	3092.56	4975.70	8751.18
Filing Date Shares Outstanding	60.17	60.19	300.48	300.48	300.48	300.48
Total Common Shares Outstanding	60.17	60.19	300.48	300.48	300.48	300.48
Working Capital	24,918	44,682	104,494	176,588	269,771	445,890
Book Value Per Share	6794.93	6828.29	1461.28	1499.30	1430.83	1913.47
Tangible Book Value	367,010	370,424	396,976	410,442	425,647	574,510
Tangible Book Value Per Share	6099.42	6154.01	1321.13	1365.95	1416.55	1911.97
Land	27,642	27,332	27,704	26,567	12,055	-
Buildings	138,112	136,640	77,472	76,415	-	-
Machinery	90,105	79,512	72,427	51,848	10,175	3,455
Construction In Progress	89,687	110,263	152,876	169,147	15,415	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.